Triple Checkpoint Inhibitor Combination for Cancer Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in breaking tolerance to self-antigen and inducing a robust anti-tumor response, particularly in effectively inhibiting tumor growth, metastasis, and achieving durable immune responses.
Innovation Solution
A combination of PD-1, TGFβ, and TIGIT inhibitors is administered to patients, either as separate or fused molecules, to enhance anti-tumor immunity by blocking immunosuppressive pathways and promoting immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer treatments are used, then tumor growth can be inhibited to some extent, but the ability to break tolerance to self-antigen and induce robust anti-tumor response is limited
Solution Approach 1:
The patent combines three different immunotherapy agents targeting distinct immune checkpoint pathways (PD-1, TGFβ, and TIGIT) into a single combination therapy regimen. This merging of multiple therapeutic mechanisms works synergistically to break tumor-induced immune tolerance more effectively than any single agent alone, while maintaining manageable toxicity profiles through coordinated action across different pathways.
Solution Approach 2:
The treatment employs a composite therapeutic approach using three different molecular classes and mechanisms of action (monoclonal antibodies against PD-1/PD-L1, TGFβ inhibitors, and TIGIT inhibitors). This composite strategy creates a multi-faceted attack on tumor immune evasion mechanisms, combining the benefits of checkpoint blockade with cytokine pathway inhibition and co-inhibitory receptor blockade to achieve robust anti-tumor immunity.
2Reliability
If single-agent immunotherapy is used, then treatment simplicity is maintained, but therapeutic benefit and tumor regression are insufficient
Solution Approach 1:
The patent integrates three separate immunotherapeutic agents into a unified combination regimen that can be administered concurrently or sequentially. This merging approach maximizes therapeutic benefit by targeting multiple immune checkpoint pathways simultaneously, creating synergistic effects that produce durable tumor regression and enhanced anti-tumor immune responses despite the increased regimen complexity.
3Reliability
If multiple immune checkpoint pathways are targeted simultaneously, then robust anti-tumor immunity is achieved, but treatment complexity and administration burden increase
Solution Approach 1:
The patent combines three immunotherapy agents into a single integrated treatment protocol that can be administered through standardized routes (intravenous infusion). This merging strategy achieves robust multi-pathway immune activation while maintaining operational feasibility through coordinated scheduling and unified administration protocols, reducing the burden on patients and clinicians compared to managing completely separate therapies.
Data Source
AI summary
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, and a TIGIT inhibitor to treat cancer.